Recent Expansions in Anti-Microbial Profile of Quinoline Analogues: A Review

The alarming rise in life-threatening infections caused by Gram-positive and Gram-negative bacteria has become a significant global health concern, urging the scientific community to explore new therapeutic solutions. Among heterocyclic compounds, the quinoline nucleus has emerged as a versatile scaffold with diverse pharmacological properties. Naturally occurring quinoline-based compounds provide a foundation for designing novel semi-synthetic and synthetic derivatives with broad-spectrum antibacterial activity. Quinoline- fused derivatives have shown potent anticancer effects by targeting critical enzymes and proteins, including topoisomerase I, telomerase, farnesyl transferase, Src tyrosine kinase, and protein kinase CK-II. Additionally, these compounds exhibit antitubercular, anticonvulsant, analgesic, and anti-inflammatory activities. Their potential as cardiovascular agents, acting as calcium-channel blockers and cAMP phosphodiesterase III inhibitors, further highlights their pharmacological significance. The fusion of quinoline with other heterocyclic systems such as indoles, pyridines, triazoles, imidazoles, and pyrazoles presents a promising strategy for drug discovery. Such combinations leverage the individual activities of each moiety, producing synergistic effects and enhancing therapeutic potential. These advances underscore the need for continued exploration of quinoline derivatives to identify novel lead compounds with improved efficacy and broadened activity spectra. This paradigm not only offers a pathway to address pressing antimicrobial resistance but also opens new opportunities for synthetic chemistry and the development of multifunctional therapeutic agents.